Skip to main content
. 2021 Dec;379(3):343–357. doi: 10.1124/jpet.121.000845

Fig. 3.

Fig. 3.

In vivo efficacy studies in GBM 22 orthotopic [intracranial (IC)] tumors treated with 50 mg/kg TMZ for 5 days with and without 60 mg/kg berzosertib. Kaplan-Meier curves for GBM 22 intracranial xenografts (n = 7–8) show no difference in survival with the addition of berzosertib to TMZ (P = 0.82).